{"name":"Kala Pharmaceuticals, Inc.","slug":"kala-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"KPI-121 0.25% Ophthalmic Suspension","genericName":"KPI-121 0.25% Ophthalmic Suspension","slug":"kpi-121-0-25-ophthalmic-suspension","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"KPI-121 0.25%","genericName":"KPI-121 0.25%","slug":"kpi-121-0-25","indication":"Dry eye disease","status":"phase_3"},{"name":"KPI-121 1.0%","genericName":"KPI-121 1.0%","slug":"kpi-121-1-0","indication":"Dry eye disease","status":"phase_3"},{"name":"KPI-121 Ophthalmic Suspension","genericName":"KPI-121 Ophthalmic Suspension","slug":"kpi-121-ophthalmic-suspension","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Vehicle of KPI-121 1.0%","genericName":"Vehicle of KPI-121 1.0%","slug":"vehicle-of-kpi-121-1-0","indication":"Treatment of non-infectious uveitis","status":"phase_3"},{"name":"Vehicle of KPI-121 0.25%","genericName":"Vehicle of KPI-121 0.25%","slug":"vehicle-of-kpi-121-0-25","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_3"}]}],"pipeline":[{"name":"KPI-121 0.25% Ophthalmic Suspension","genericName":"KPI-121 0.25% Ophthalmic Suspension","slug":"kpi-121-0-25-ophthalmic-suspension","phase":"phase_3","mechanism":"KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Post-operative ocular inflammation"],"catalyst":""},{"name":"Vehicle of KPI-121 1.0%","genericName":"Vehicle of KPI-121 1.0%","slug":"vehicle-of-kpi-121-1-0","phase":"phase_3","mechanism":"KPI-121 is a corticosteroid","indications":["Treatment of non-infectious uveitis"],"catalyst":""},{"name":"KPI-121 0.25%","genericName":"KPI-121 0.25%","slug":"kpi-121-0-25","phase":"phase_3","mechanism":"KPI-121 is a topical ophthalmic formulation that reduces ocular surface inflammation and promotes tear film stability through a mucoadhesive delivery system.","indications":["Dry eye disease","Ocular surface inflammation"],"catalyst":""},{"name":"KPI-121 1.0%","genericName":"KPI-121 1.0%","slug":"kpi-121-1-0","phase":"phase_3","mechanism":"KPI-121 is a topical ophthalmic formulation that reduces ocular surface inflammation and promotes tear film stability through a mucoadhesive delivery system.","indications":["Dry eye disease","Post-operative ocular inflammation"],"catalyst":""},{"name":"KPI-121 Ophthalmic Suspension","genericName":"KPI-121 Ophthalmic Suspension","slug":"kpi-121-ophthalmic-suspension","phase":"phase_3","mechanism":"KPI-121 is a topical ophthalmic suspension that reduces ocular inflammation and promotes corneal healing through inhibition of transient receptor potential vanilloid 1 (TRPV1) and modulation of inflammatory pathways.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Ocular surface inflammation"],"catalyst":""},{"name":"Vehicle of KPI-121 0.25%","genericName":"Vehicle of KPI-121 0.25%","slug":"vehicle-of-kpi-121-0-25","phase":"phase_3","mechanism":"KPI-121 is a corticosteroid","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1WVmlTNXoza0VDbDhzNjROTGhlMmxsVk9saEJicFJtRkJFRFFYdlpIdFVGLU50d1hMX0I5Q1FnWnhtUDVjeklvTUdOMWpocUJ0R24tZnc5enc5SGs2UkRjQzZiRVYzbzI1dEV3Z1V3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan","headline":"If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNeGdvaHhLUXR6OHJPQnRyU2pBT1AwVnhxZnV1TlBHOVU1T1VfUjc5TW5fZzRVYTV5ZXJRYnRqcF82RWctOFNTR3JURVJNc2tlMS13dUFOd3QtWk44ZTFqWC1SeXJFcTNxcTkwNFVWU09CdEVDRXYwbk91MDNhM04xYU94YTFQQTZ0WmJrajJEM3k4bkFJOUJLaHc0MFNLNEc0VUJ5TnhKUmJwY0E2MEVfV0kyQ1UtLVlqVnMybkJQRQ?oc=5","date":"2026-03-11","type":"pipeline","source":"Stock Titan","summary":"$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan","headline":"$180B AI healthcare play: KALA BIO pivots with first agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWDhuLVEyNG8xYXFsc05iTlBIS2pIWUxubmNfdEFlc2xLTjhtTEpOZE02Nm1jTU1qaURxc2U4X0xmS0c4Qk5qZ09aNXJBZ0ZLYUJoS213VUFOelBWZ21VdXBDcWV6SkQyVnBGQktZX1JWMEhVZTI1ZUpwYm9nVW1HNFNCdUpiVERnbktneWZzSG9RekpJVE1vcFFjaE5BRlgyVWw3NlNaM2ZzOHZLQkhMNzZJbWI5QjRM?oc=5","date":"2026-03-04","type":"pipeline","source":"Benzinga","summary":"What's Going On With KALA BIO Stock Wednesday? - Kala Bio (NASDAQ:KALA) - Benzinga","headline":"What's Going On With KALA BIO Stock Wednesday? - Kala Bio (NASDAQ:KALA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNX013LV9HVkszZWtOTU5yQWVUemxhQzAwdFo5Tm1SREJROWR6UmFKWlFQR3AxTmxXcHJlblZpSlI3RVBzSEY3U2YzTXcweXhDQ0dVenc3S3ByM19LLWVySEdYVWtPX2lCczRTcnctUXZoZFFRaEdzLXkxMTRWZWpNTVd4UjRaSXlNWUpjSjVxYk52S25aWUhETmdFdzEwbE5VNFdLV0ZOOVl5MGdTY3dQd1U5THNIc1pYRkRsSA?oc=5","date":"2026-03-04","type":"trial","source":"Stock Titan","summary":"Biotech data stays in-house as KALA BIO bets on on-prem AI for drug R&D - Stock Titan","headline":"Biotech data stays in-house as KALA BIO bets on on-prem AI for drug R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcUNidWJzam1hN2tYUzhFVjZuazNLTzdSai1nUkJmR0tJNnk1SFZJZDZFS3hHSW1YZWRjTXRobWxoX29lWmtXX09TMmp2b1Vpb3B3TmJLY3Y4OWFQTjJXRXg2bmRTcnNYdnowVExiNWFpY0pidUoxcHRaRms3bHMzaklwREdsYnNmSmo1b0c4dDA5TEZ1N0lqNzhLSG9kR3RVbDdkZHhqakQ?oc=5","date":"2025-11-26","type":"pipeline","source":"Benzinga","summary":"What Sparked KALA BIO's Nearly 38% Surge Overnight? - Kala Bio (NASDAQ:KALA), NovaBay Pharmaceuticals (AM - Benzinga","headline":"What Sparked KALA BIO's Nearly 38% Surge Overnight? - Kala Bio (NASDAQ:KALA), NovaBay Pharmaceuticals (AM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQTURaUzBuRHZSRkJyU0lSX2V5VTUwa0xocGIwb2xCbllsMHd4MUdCRVEtUmhNX0Z1V053NkV5RFl6SF84cHBSUVFtLXR4RzVaaFBTamJ0dXNlYlZ3dF9tdnFhTjRyY0dUNHJOakw0RnZybmtYTHlNS2pkT3hIR3FvdTlVT29Kcl92T3pnd0JJVTZUM0lsMlNjdjZQckVfUGJhek5TeVE3dHVlLWZGV2pFS0l4Qkd0UWhxbzEzb0s3c0hRYzZfRzBN?oc=5","date":"2025-09-30","type":"regulatory","source":"Stocktwits","summary":"Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery - Stocktwits","headline":"Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Rec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOd01rWmxUVWtaRHhpRURfNklZVkpaNnlXRnZHZFpyREtxNW9aRE9yUjJUTlNmVjRRaDJ6ZXVtSFllTnY2cmlQS05GdVUxNHlxNjc0VDBCb25Yd2Q4WlR5NGFFUDJ4MHZwbmV5Q2h5SmQ1N3hoS0ozMzFscW5NWXFDOUozY3dsdDAxRlZJUXc2aTN2Q25YdWNvRG1ORUZLaXBWWU8yMWRQTDJNa1BNUWpmUHdIcXpQakZfd3NheE5HMA?oc=5","date":"2025-09-29","type":"pipeline","source":"Stocktwits","summary":"Kala Bio Stock Just Plunged 89% Today – Here’s What Happened - Stocktwits","headline":"Kala Bio Stock Just Plunged 89% Today – Here’s What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORW5YT3BDdDhwZG1kYjI5YWg2NWFsRDcwb21VX3RkbDFwcjZYcXQ4MFFKcEo2Zk5QeGdjd2UzWWo2b0c1NGUyZGFtdUpMMDRIaDVpRjVMRU05dlNtZ2Rja3ZSZVk5ZERoMFZfbUlsZWROZkpQNG9OX0dPN3Y3elhsazNJODl3VUVkbjNDVnFaaERnZ1E?oc=5","date":"2025-07-10","type":"regulatory","source":"The Business Journals","summary":"FDA publishes drug rejection letters for 15 Massachusetts biotechs - The Business Journals","headline":"FDA publishes drug rejection letters for 15 Massachusetts biotechs","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObTMydGNtQlFXLUpDMGxFSmNoUW8zdVhYcW85aVhWU3lrb2Flem1KNEtHWmVnTDJ4ZzA2dV9xUnlVZVpIOVRVUlhKa3ZqbkVhUFpCY2s5Q2xqNTU0dmJxZEdWMjRrV1FBY084eGMySEdJSjJxb28zWVRYZnliSjZIZk5lU1FEdlBEdkUyUmx0NC1WcjRneElLVlBSVng3d2FOMGZLcVhmM2tTUQ?oc=5","date":"2025-05-29","type":"regulatory","source":"Fierce Pharma","summary":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease - Fierce Pharma","headline":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPbm5na3ZKdWJEdWZyektkd0FhZG54VThTZWFtdU5DQlBISXYyNGZmd1dZYlBSSGhMZ3hsUHlVVWZMeElOOVV6UnFhelc1eWNyd09UdlpVWHFrT2ROc3p5RnpQZVp1NGF2SW5GY1pUQ3FvcGdJVnN3WExJdXdYb0liMEV1R2txaGtEQkUzODVZSVJXZVA0cVYxOFZMaWl2SWFGckVnRjVxM0paQVM5QXBqWEFJT25SVkZLakwzeHR0cw?oc=5","date":"2022-10-20","type":"pipeline","source":"GlobeNewswire","summary":"Kala Pharmaceuticals Announces Reverse Stock Split - GlobeNewswire","headline":"Kala Pharmaceuticals Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQUUpoeTZ3MzZLMXc0aHZVLWVHYS10dkpPdzJzblhubVBicUVRVGJZRHFHcXF6VHhrbHNWWWlLRG5GWDgtdDJwZnlPTk1NMVEwYm0xMDh2Tmg4X096enlBVlRFcnZGal9rWVdzYXhOM0NJWUpXZ3FCd1RVMUFTeG5acmxkYy0?oc=5","date":"2022-08-23","type":"deal","source":"Ophthalmology Times","summary":"Alcon to acquire Aerie Pharmaceuticals - Ophthalmology Times","headline":"Alcon to acquire Aerie Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1XeFd3d0diYXVNLTd6ZGNuTTdJTjdXODJ4S2syZjhJeTFsanY5TnF3eEw1OEFKZS1mVjFWTzZKWDVldFlPck9iZm5YVzVSQUhwdWJZOVpxNE5tSkZZRGhvWU5STFBjMHdRczFRbEZlLTl1YUZqemUwb2RWdGU?oc=5","date":"2021-01-25","type":"pipeline","source":"pharmacytimes.com","summary":"Eysuvis From Kala Pharmaceuticals, Inc - pharmacytimes.com","headline":"Eysuvis From Kala Pharmaceuticals, Inc","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":6},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}